Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: implications for combination therapies

(2019) Yijun Jia et al.   INTERNATIONAL JOURNAL OF CANCER

High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs

(2019) Chao Deng et al.   MEDICINE

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non–Small-Cell Lung Cancer: A Prospective Observational Study

(2018) Tomoya Fukui et al.   Clinical Lung Cancer

Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients

(2018) Dong Guo et al.   Future Oncology

Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

(2018) Noriko Nishinarita et al.   ONCOLOGY

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs

(2018) Yuan Zhang et al.   MEDICINE

Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer

(2017) Kylie H Kang et al.   Future Oncology

Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District

(2017) Pei N. Ding et al.   INTERNAL MEDICINE JOURNAL

Significance of Neutrophil-to-lymphocyte Ratio in Western Advanced EGFR-mutated Non-small Cell Lung Cancer Receiving a Targeted Therapy

(2017) Fausto Meriggi et al.   TUMORI

Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden—Reply

(2017) Christina Fitzmaurice et al.   JAMA Oncology

Significance of Neutrophil-to-lymphocyte Ratio in Western Advanced EGFR-mutated Non-small Cell Lung Cancer Receiving a Targeted Therapy

(2017) Fausto Meriggi et al.   TUMORI JOURNAL

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

(2016) Jun Wang et al.   OncoTargets and Therapy

Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy

(2016) Noriyuki Hirahara et al.   BMC Surgery

Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations

(2015) Satoshi Igawa et al.   ONCOLOGY

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Microenvironmental regulation of therapeutic response in cancer

(2015) Florian Klemm et al.   TRENDS IN CELL BIOLOGY

Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment

(2014) Gui-Nan Lin et al.   Asia-Pacific Journal of Clinical Oncology

Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer

(2013) J. G. Aerts et al.   CANCER RESEARCH

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

(2012) Fausto Petrelli et al.   Clinical Lung Cancer

Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma

(2012) David James Pinato et al.   Journal of Thoracic Oncology

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

(2011) E. Bria et al.   ANNALS OF ONCOLOGY

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability

(2009) F. Colotta et al.   CARCINOGENESIS

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE